EBV Antibody to Nuclear Antigen
Test Mnemonic
EBVNA
CPT Codes
- 86664 - QTY (1)
LOINC ®
31372-6
Aliases
- Epstein Barr Virus NA Antibody
Performing Laboratory
Cleveland Clinic Laboratories
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Refrigerated |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 24 hours |
| Frozen | 14 days |
| Refrigerated | 7 days |
Days Performed
Sun - Fri
Turnaround Time
1 - 2 days
Methodology
| Name | Description |
|---|---|
| Chemiluminescence Immunoassay (CLIA) |
Reference Range
| EBV Antibody to Nuclear Antigen | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | Refer to report | U/mL |
Special Info
Avoid hemolysis. Avoid multiple freeze thaw cycles.
Clinical Info
EBV nuclear antigen (EBNA-1) IgG typically appears from several weeks to several months after primary EBV infection and may remain elevated for life but it may become equivocal or undetectable in certain immunocompromised individuals. The final interpretation should be done in the context of other EBV serology panel results.
Clinical Limitation
Assay performance has not been established for immunocompromised or immunosuppressed patients. Assay performance has not been established for cord blood, neonatal specimens or infants. There is a possibility of assay cross-reactivity with specimens containing anti E-coli antibody. Assay performance has not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt's lymphoma, other EBV-associated lymphomas, and other EBV associated diseases other than EBV related mononucleosis. Testing should not be performed as a screening procedure for the general population. It should only be performed when clinical evidence suggests the diagnosis of EBV-associated infectious mononucleosis. If the marker is negative and exposure to EBV is suspected, a second sample should be collected and tested no less than one-two weeks later. In cases of equivocal results, a second freshly collected sample should be obtained and tested.